192 results about "Molecular typing" patented technology

The invention relates to the functional genomic and gene expression detection technology and the analysis technology, and discloses a reagent kit for quantitatively assessing long-term recurrence risks of breast cancer. Particularly, a type of genes capable of being used for breast cancer metastasis and prognostic molecular classification is screened within a human functional genome expression profile range, the detection technology is created, and the reagent kit is prepared and applied to breast cancer metastasis and prognostic assessment for a patient. The reagent kit for quantitatively assessing long-term recurrence risks of breast cancer comprises 21 pairs of primers, 21 specific taqman fluorescent probes, 10XRT-PCR (reverse transcription-polymerase chain reaction) buffer solution, 2.5mM of dNTP (diethyl-nitrophenyl thiophosphate) mixed liquor, reverse transcriptase, DNA (deoxyribose nucleic acid) polymerase, 10XPCR buffer solution and RNA (ribonucleic acid) enzyme inhibitor. The reverse transcription PCR technology is combined with the taqman fluorescent quantitative PCR technology, reverse transcription primers, real-time PCR primers and the taqman fluorescent probes are self-designed and optimized, reverse transcription PCR reagent and taqman fluorescent quantitative PCR reagent are integrated to prepare the detection reagent kit, operation is simple and fast, detection results are more stable, and detection cost is lower.

The invention provides molecular typing of diffuse gastric cancer and protein markers for typing and a screening method and application thereof, and discloses protein expression profile data of tissues of 84 cases of diffuse gastric sample cancer and tissues adjacent to the cancer, a method for typing of the gastric cancer based on the protein expression profile data and 199 protein markers for gastric cancer typing. The method can be used for typing of the diffuse gastric cancer in Lauren typing into three subtypes comprising cell cycle diffuse gastric cancer PX1, epithelial-mesenchymal transition diffuse gastric cancer PX2 and immunoenriched diffuse gastric cancer PX3. The invention provides a method for classification, diagnosis and prognosis of the gastric cancer, and lays a foundationfor prognosis of the diffuse gastric cancer and designing of targeted drugs.

A tumor molecular typing prediction system comprises a gene expression data extraction module, a missing value preprocessor, an important gene extraction module and a US-ELM (Extreme Learning Machine) molecular typing module, wherein the gene expression data extraction module is used for obtaining tumor gene expression data; the missing value preprocessor is used for filling the obtained tumor gene expression data with missing values; the important gene extraction module is used for extracting important tumor genes determining survival time from the tumor gene expression data; the US-ELM molecular typing module is used for performing tumor molecular typing prediction on the important tumor genes by adopting US-ELM. The tumor molecular typing prediction system overcomes the defects of slow speed, poor generalization performance and low classification accuracy of conventional tumor molecular typing techniques, realizes tumor molecular typing prediction which is rapid and high in classification accuracy, and can perform unsupervised machine learning on multiple types of tumors. By the application of the system in tumor molecular typing prediction, biological behaviors of the tumors can be better judged, and the direct purpose of the system is to provide the reference base for formulation of personalized treatment programs instead of obtaining a diagnosis result.

It is provided a method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type in view of molecular typing which is different from a conventional histopathology, and a marker for identification of a tissue-type of epithelial ovarian cancer. A method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type, comprising: subjecting a sample originated from an individual of interest to a treatment for detecting at least one selected from the group consisting of biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and / or at least one selected from the group consisting of biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer, and identifying whether or not the significant detection of the protein is achieved, thereby identifying the tissue-type.

A model for prognosis prediction of breast cancer patients is characterized in that joint judgment is performed by ten lncRNAs expression quantities. The established model can predict prognosis of thepatient more accurately and individually, better guide clinical decision, provide reference for selection of a treatment scheme of the patient and reduce unnecessary treatment, and has important significance for accurate diagnosis and treatment of breast cancer. In view of the limited prognosis evaluation capability of the current breast cancer TNM staging system and molecular typing on patients,the model makes an effective progress for the research in the direction. According to the method, the prognosis condition of the patient can be accurately evaluated, and the model has very high practicability and guidance.

The invention relates to a biomarker combination for molecular typing and / or prognosis prediction of the muscle-invasive bladder cancer, and a screening method and application thereof. The biomarker combination comprises the following genes: FGF10, TP53INP1, DDR2, MYC, CDC73, IGF1, PLA2G1B, SKI, FN1, EGFR, PPARG, PDGFRA, PDGFD, GAS6, PDGFC, FNTB and CCNB1. Through non-negative matrix factorizationclustering analysis based on transcription data of the biomarker combination, the muscle-invasive bladder cancer can be classified to respectively correspond to different expression characteristic spectrums. The classification corresponds to significantly different overall survival statuses, thus being used for survival prognosis assessment. The transcription data analysis method adopted has theadvantages that the number of biomarker combinations is small, the analysis steps are simple, the requirements of large sample analysis are met, the requirements for the calculation ability are low, and the method is applicable to standardized transcription data; the transcription data can be a transcriptomic data sub set or a set of genetic transcription data for individual detection.

The invention discloses a glioma EM / PM molecular typing method based on a Taqman low-density chip and application of the glioma EM / PM molecular typing method, and provides a Taqman low-density chip product capable of specifically implementing EM / PM molecular typing and a matching kit, and a model constructed by an EM / PM typing algorithm based on a support vector machine. By using the chip and themodel, patient EM / PM typing and individualized diagnosis can be completed quickly and conveniently, and guidance on risk stratification and individualized medication can be given to patients. Comparedwith the situation that expression profile detection typing based on an Affymetrix chip or mRNA seq needs to be completed for 7-10 days, typing can be completed in only one working day through the detection method, meanwhile, the used chip and detection instruments are detection instruments which are always available in a laboratory, and no additional large equipment (such as an Affymetrix chip detection system or a high-throughput sequencing instrument) is required.

The invention provides a tracing method of cronobacter spp. in infant formula milk powder. The method comprises the steps that by means of a multiple-locus sequence typing technology, molecular typing research is conducted on the cronobacter spp. of PIF raw materials, semi-finished products, finished products and processing environments thereof, population characteristics of the cronobacter spp. are revealed, a phylogenetic relationship of the cronobacter spp. is confirmed, phylogenetic analysis is conducted on the cronobacter spp. through bioinformatics, and therefore genetic characteristics of the cronobacter spp. in the above-mentioned environments are revealed systematically; on the basis of cronobacter spp. MLST typing, correlation analysis is conducted by taking ST of pathogenic bacteria and environmental sources as variables, key links which are most prone to pollute the cronobacter spp. in the PIF processing process and distribution rules are determined, and therefore the source of the cronobacter spp. in the infant formula milk powder is traced. The purpose of fundamentally monitoring the PIF production process and ensuring the PIF quality are achieved.

The invention provides a ovarian cancer molecular typing prediction system. The system mainly comprises the following steps of step1, using an ovarian cancer mRNA gene expression characteristic data extraction module: acquiring ovarian cancer gene expression data; step2, for all gene expression data, using a preprocessing. scale method in skleam to carry out standardized processing, and accordingto a formula which is Z-scroce=(x-mu) / S<2>, and processing each mRNA expression spectrum data into data submitting to normal distribution with the mean value of 0 and the variance of 1; step3, selecting main characteristic gene data: using principal component analysis (PCA) and a Filter characteristic selection method; step4, using a BP neural network to carry out genetic data training model withN characteristics; and step5, using a certain amount of samples to carry out callback program verification. In the invention, through an ovarian cancer pathological section, automatic machine identification and error reporting can be realized, and rapid and accurate ovarian cancer molecular typing prediction is achieved; and the system is used to carry out ovarian cancer molecular typing prediction so that a clinical treatment plan can be improved.

The invention provides a tumor molecular typing method and device, terminal equipment and a readable storage medium, and the method comprises the following steps: obtaining sequencing data of a plurality of tumor tissue samples, and calculating a copy number value; screening mutated genes in each tumor tissue sample; performing unsupervised clustering on the mutated genes to obtain a plurality of sample categories; screening genes with significant gene copy number variation among samples of each sample category, and performing unsupervised clustering to obtain a plurality of gene categories; calculating a first principal component based on the copy number variation, and determining the influence of the first principal component on the prognosis of the patient through regression analysis; and calculating copy number variation scores of the tumor tissue samples according to the influence of the first principal component on the prognosis of the patient, and classifying the samples of the sample categories according to the copy number variation scores to complete the molecular typing of the tumor. Molecular typing is carried out based on copy number variation of each gene, the resolution ratio is high, typing is accurate, and prognosis of tumor patients with different molecular types can be remarkably distinguished.

The invention relates to a cancer precise chemotherapy typing marker screening method, a chemotherapy sensitivity molecular typing method and application. According to the method, a typing marker is obtained from a multi-center and large sample queue to discover molecular typing, and a classifier is constructed by using the typing marker or differential protein obtained based on a typing label asa selection characteristic; when the classifier carries out classification application, expression profile data of a collected sample is input; and after expression spectrum data preprocessing, classifier feature matching and logarithm conversion are performed, prediction is performed by the classifier constructed through a machine learning classification algorithm or an artificial intelligence model; and finally an output label of a chemotherapy sensitive group or a chemotherapy insensitive group is obtained, and molecular typing of accurate chemotherapy is performed, so that the problem of pain spots in the field of tumor medical treatment is solved, wherein the problems comprise: accurately judging whether chemotherapy is beneficial to people, providing first-line medication regimen optimal combination recommendation and providing chemotherapy regimen optimal period recommendation.

The invention provides a group of thyroid cancer markers and an application thereof. The markers comprise thyroid cancer molecular typing related genes, targeted medication related genes, chemotherapymedication related genes, operation prompt related genes, prognosis related genes and thyroid cancer heredity related genes. According to the invention, aiming at all exon regions of 44 genes relatedto thyroid molecular typing, targeted medication, chemotherapy medication, operation prompt, prognosis and heredity, high-depth sequencing is carried out; meanwhile, various variation types like SNV / Indel and gene fusion of genes are analyzed; and molecular level information of thyroid nodules and thyroid cancer is deeply analyzed. Aiming at a capture probe designed for the 44 genes, 558 targeting target regions are covered; the probe comprises 3633 sequences with a total size of 254.096 Kbp; and a prepared kit is wide in coverage, high in cost performance and high in effectiveness, can provide a reference basis for further molecular typing, medication prompt, genetic risk assessment and the like of a thyroid patient, and is applicable to clinical popularization and application.

The invention discloses a genome for molecular typing of medulloblastoma. The genome for molecular typing of medulloblastoma includes the following 24 genes: EPHA7 gene, OTX2 gene, ROBO1 gene, TTR gene, LGR5 gene, IGF2BP3 gene, TBR1 gene, ZFPM2 gene, TRDC gene, TRAC gene, PEX5L gene, NKD1 gene, RALYL gene, GABRA5 gene, GAD1 gene, TNC gene, KCNA1 gene, EOMES gene, MAB21L2 gene, WIF1 gene, DKK2 gene, PDLIM3 gene, IMPG2 gene, and KHDRBS2 gene. In addition, the invention also discloses an application of the genome in preparing a kit and a gene chip for molecular typing of medulloblastoma. As proved by experience, the method can accurately distinguish the WNT type, the SHH type, the Group3 type and the Group4 type of medulloblastoma, and has the advantages of objective result interpretation, high accuracy and short experiment period, and has important clinical significance in carrying out precise treatment on patients.

The invention belongs to the technical field of biology, discloses a gene group capable of evaluating primary lung adenocarcinoma molecular typing and survival risk, and discloses application of reagents for detecting gene expression levels of the gene group in preparing in-vitro diagnostic products for evaluating primary lung adenocarcinoma molecular typing and survival risk. The in-vitro diagnostic products comprise a Next Generation Sequencing (NGS) detection kit, a fluorescent quantitative PCR detection kit, a gene chip and a protein array. The invention further discloses a method for evaluating primary lung adenocarcinoma molecular typing and survival risk by utilizing the detection kits. The method disclosed by the invention has high accuracy on evaluation of primary lung adenocarcinoma subtype typing and survival risk.

The invention provides a set of genes for head and neck squamous cell carcinoma (HNSCC) molecular typing. The set of genes comprises TP53 gene, CDKN2A gene, FAT1 gene, CASP8 gene, AJUBA gene, PIK3CA gene, NOTCH1 gene, KMT2D gene, NSD1 gene, HLA-A gene, HRAS gene, FBXW7 gene, RB1 gene, PIK3R1 gene, TRAF3 gene, NFE2L2 gene, CUL3 gene and PTEN gene. The invention also provides application of the genes in preparing a kit and gene chip for HNSCC molecular typing, and a kit and gene chip for HNSCC molecular typing prepared by using the genes. The genes can enhance the HNSCC typing rationality and accuracy, thereby providing key technical supports for implementing early diagnosis, effective interception and individualized treatment on HNSCC.

Molecular methods are provided for typing group B streptococci, as well as polynucleotides useful in such methods.

The invention provides a novel coronavirus SARS-CoV-2 detection and molecular typing method and a kit. The method utilizes the combination of one-step multiple RT-PCR and HRM analysis to simultaneously realize the detection and typing of SARS-CoV-2. The detection method comprises the following steps of: 1) extracting sample nucleic acid; 2) completing one-step multiple RT-PCR reaction in a special primer group and a reagent; and 3) analyzing and interpreting SARS-CoV-2 detection results and molecular typing results by HRM. The kit provided by the invention comprises multiple special primers for detecting SARS-CoV-2 and performing molecular typing on the SARS-CoV-2, and also comprises reaction components Master Mix (RNA reverse transcriptase, polymerase, amplification buffer, dNTP and EvaGreen fluorescent dye), positive control and negative control.

The invention provides a tumor-targeting near-infrared fluorescent probe and a preparation method thereof, and is characterized in that the fluorescent probe comprises a cyanine fluorescent dye part and a targeting carrier part; the cyanine fluorescent dye part and the targeting carrier part are coupled by covalent bonds, wherein, the cyanine fluorescent dye part comprises IDCC and ITCC, and the targeting carrier part comprises EBP molecules. After entering a body, the tumor-targeting near-infrared fluorescent probe reaches tumor tissue and is bonded with EGFR of cells, and exhibits a strong effect of targeted fluorescent labeling, thereby not only improving the specificity and the sensitivity of tumor fluorescence imaging significantly, but also providing important information for the evaluation of molecular typing and molecular targeted drug efficacy of tumors, and having strong practicality for guiding and monitoring the application of molecular targeted drugs.

The invention relates to a method for analyzing molecular typing based on gastric mucosal lesion proteomics, different gastric mucosal lesion proteomics molecular subtype characteristics and correlation between the molecular typing and the subtype characteristics and the gastric mucosal lesion progress. A protein marker database related to gastric cancer and gastric mucosal lesion progress is established by calculating the relationship between protein expression and gastric mucosal tissue pathological state, proteome molecular subtype and gastric mucosal lesion progress, and a gastric mucosallesion sample disease progression risk scoring system is established. According to the invention, a molecular epidemiological research means is combined with bioinformatics analysis and machine learning, microscopic and macroscopic gastric cancer cause risk factors are integrated, a gastric mucosal lesion molecular typing framework and a progress risk prediction model are established, and a foundation is laid for finally constructing a comprehensive and systematic gastric cancer prevention strategy.

The invention discloses a pepper and tomato bacterial streptomyces scabies MLST molecular typing method, and discloses a multilocus sequencing typing (MLST) method for the first time. The method is an operation technology for molecular typing on pepper and tomato bacterial streptomyces scabies. The method comprises the following steps: extracting DNA of genome of pathogenic bacteria, and screening, amplifying, detecting and sequencing seven house-keeping genes; carrying out multi-sequence comparison and analysis on a sequencing result by DNAMAN software to obtain a bacterial strain sequence type; and analyzing the sequence type by using an eBURSTV3 program in an online manner, so that four kinds of pathogenic bacteria can be distinguished effectively. Combination of the seven house-keeping genes and amplification primers which are used in the typing technology are used for the first time, and a PCR reaction system and conditions are optimized voluntarily. The technique process can be used for classification, identification and genetic diversity research of the pepper and tomato bacterial streptomyces scabies.

The invention belongs to the technical field of biology, and particularly relates to a gene mutation site group of NK / T cell lymphoma and a kit and application thereof. The invention provides a gene mutation site group of NK / T cell lymphoma, which can be used for evaluating molecular typing of NK / T cell lymphoma, predicting prognosis of a patient and guiding medication of the patient. According tothe kit, an IlluminaMiseq sequencing platform and performance sequencing are adopted, a series of mutant genes related to NK / TCL diseases can be efficiently and accurately detected, the detection period is short, the detection cost is low, the application range is wide, and the accuracy is high.

The invention belongs to the field of microorganism molecular typing and particularly relates to a primer and a method for fast typing campylobacter jejuni. The primer includes 13 pairs of campylobacter jejuni primers. The primer is good in typing capacity, high in distinguishing index and capable of accurately typing the campylobacter jejuni. In addition, the method for fast typing the campylobacter coli is simple and fast to operate, good in stability and repeatability, capable of effectively assisting the clinical diagnosis of diseases infected by the campylobacter jejuni and ideal.

The present invention relates to a high sensitivity assay for molecular typing of a biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); capture probes for capturing nucleic acid; a detector probe to detect captured nucleic acid; a kit for molecular typing of biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); and lastly a method of manufacturing said kit.

The invention provides a noninvasive molecular subtyping kit and method for a breast cancer and aims to provide a kit which is simple to use and high in detection accuracy and a noninvasive molecularsubtyping method for a breast cancer, which makes samples easy to obtain, is simple in sampling process, good in clinical experience, capable of achieving processized operation and very suitable for clinical application and non-disease diagnosis purposes. The technical scheme of the invention is that the noninvasive molecular subtyping kit for the breast cancer comprises a plasma free DNA extraction reagent, a library construction reagent, a sequencing reagent and a sequencing chip. The method is based on high-throughput sequencing data of plasma free DNA, nucleosome footprint difference information of a promoter region in the whole genome range in the plasma free DNA is obtained by means of bioinformatic analysis, and thus noninvasive molecular subtyping of four categories of a lumen A type, a lumen B type, an HER2 enrichment type and basal cell type of a breast cancer patient is achieved according to the difference of footprint information. The invention belongs to the technical field of biology.

The invention relates to a breast cancer molecular typing method, device and system based on unsupervised learning. The method comprises the following steps: obtaining a to-be-predicted breast DCE-MRI image, and extracting regions of interest of sequence images of various specifications in the image; utilizing a molecular subtype prediction model obtained by adopting unsupervised learning training to predict and obtain molecular subtype classification probabilities corresponding to various sequence images; adopting ensemble learning fusion to obtain a final corresponding molecular subtype classification result. When the molecular typing prediction model is trained, through the thought of an unsupervised learning pre-training network and a transfer learning fine tuning network, a breast benign tumor image is fully utilized to construct an unlabeled source domain data set in the previous stage, and the feature extraction capability of the model is enhanced; and in the later stage, a target domain data set with a label is constructed by adopting the breast malignant tumor image to carry out fine tuning on the model with the pre-training weight. Compared with the prior art, the prediction precision of breast cancer molecular typing is remarkably improved.

The invention belongs to a kit used for carrying out rapid molecular typing determination upon vibrio parahaemolyticus pathogenicity. Specifically, vibrio parahaemolyticus species-specific genes tlh and toxR and virulence genes tdh and trh are detected by using F0F1-ATPase molecular motor biosensors Chro-tlh, Chro-tdh, Chro-trh, and Chro-toxR in the kit. On the one hand, with the detections upon species-specific genes tlh and toxR, a target strain can be identified. On the other hand, with the detections upon tdh and trh, the target strain pathogenicity can be determined. A method comprises that: F0F1-ATPase molecular motor biosensors in the kit are constructed; molecular typing is carried out by using the F0F1-ATPase molecular motor biosensors; and vibrio parahaemolyticus pathogenicity is determined according to a typing result. The kit has the advantages of high sensitivity, high speed, simple operation, and low cost.

The invention discloses a method and a system for extracting an immunotherapy neoantigen. The method comprises the following steps: S1, acquiring conventional proteomes of a tumor tissue and a normaltissue of a sample; S2, obtaining a base monomer unit sequence library of a sample tumor tissue and a sample normal tissue and a specific proteome of the sample tumor tissue; S3, based on the conventional proteome of the sample tumor tissue, the specific proteome of the sample tumor tissue and human leukocyte antigen (HLA) molecular typing, obtaining a plurality of candidate tumor specific neoantigens; S4, based on the plurality of obtained candidate tumor specific neoantigens, respectively calculating the existence conditions in a sample tumor tissue conventional proteome, a sample normal tissue conventional proteome, a sample tumor tissue basic group monomer unit sequence library and a sample normal tissue basic group monomer unit sequence library, and taking the existence conditions andgene expression change multiples as filtering rules to obtain the tumor specific neoantigen. From the aspect of source, the tumor specific neoantigen part discovered by the scheme of the invention comes from a genome non-coding region and is not limited to a coding region, so that more neoantigens can be discovered.

The invention relates to a non-invasive imaging screening and minimally invasive sampling nucleic acid typing combined detection system. The system comprises a non-invasive telecentric imaging health analysis system and a minimally invasive sampling multi-channel nucleic acid amplification parallel detection system; the non-invasive telecentric imaging health analysis system is configured to shoot a local surface image of the subject and perform machine learning and clustering analysis on the shot local surface image of the subject to obtain the subject with image feature abnormal change; the minimally invasive sampling multi-channel nucleic acid amplification parallel detection system is configured to perform minimally invasive sampling on a subject with abnormal change of image features, and perform detection and analysis of medical molecular typing indexes or physiological and pathological change indexes on the minimally invasive sampling to obtain specific gene detection results of the typing indexes or the physiological and pathological change indexes. According to the system, artificial intelligence conjoint analysis is carried out by combining detection results of noninvasive telecentric imaging screening and minimally invasive sampling nucleic acid accurate typing, mutual investigation is carried out, the probability of missing detection of a single method is reduced, the accuracy of detection and identification is improved, and the onset risk condition is evaluated or predicted and early-warned.

The invention discloses a molecular subtyping method for salmonella typhimuria and a specific SNP locus combination. The invention provides an application of a substance for detecting 16 SNP loci nucleotide in a genome of a to-be-detected salmonella typhimurium in preparing a product for detecting or auxiliarily detecting the molecular subtyping condition of the salmonella typhimuria, or an application of a substance for detecting 16 SNP loci nucleotide in a genome of a to-be-detected salmonella typhimurium in preparing a product for detecting or auxiliarily detecting the molecular subtyping condition. The experiment verifies that the research and development sample amount exceeds 6000for the clinically common blood serum salmonella typhimuria for molecular subtyping to obtain an SNP locusset of the molecular subtyping. Corresponding probe can be designed by using the set. The salmonella typhimuria are quickly typed in experiment. The method is short in time and low in consumable. Inaddition, the mouse typhus salmonella genotyping difficulty is greater than of the salmonella typhimuria, so that research and development of the molecular subtyping for mouse typhus salmonella is ofextremely value.

The invention discloses application of an SRGN gene and polypeptide thereof in serving as a detection marker for breast cancer molecular typing, in particular to application of the SRGN gene and the polypeptide thereof in serving as a serum marker for detecting a triple-negative breast cancer or in preparation of a detection reagent for the triple-negative breast cancer, and provides a novel breast cancer serum marker, that is, the SRGN gene and the polypeptide thereof. It is proved that expression of the SRGN gene in breast cancer serum is enhanced, and expression of the SRGN gene in serum of a triple-negative breast cancer patient is mainly and significantly increased compared with expression of the SRGN gene in serum of a breast cancer patient with the other molecular types. Accordingly, not only is a new target supplied to breast cancer serology detection, but also new data and a quick serology detection method are supplied to breast cancer molecular typing; a new chemical entity is designed at the gene level and the protein level by taking the gene as the target, breast cancer molecular typing can be quickly, conveniently and effectively performed, and therefore the breast cancer treatment effect is improved.